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Abstract Placebo and placebo effect
are important issues related to the
drug therapy for clinical and scien-
tific meanings. The rates of placebo
may get as many as 50% for anal-
gesic drugs in headache. The high
answer to placebo brings questions
on pathophysiology of headache.
Answers may offer a new strategy in
the implementation of trials and new
insight in neurophysiology of
headache. Current knowledge on
placebo and placebo effect will be
analysed and dicussed looking for
new direction in headache field.
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Introduction
The placebo effect per se is evidence of the reciprocal
influence of the mind and brain. Pain is not related to
chemical and neural transmission only: desire and
expectancy of pain relief, as cultural and individual fac-
tors, are direct components of pain and pain reduction.
A primary role of medicine is to diagnose and treat a
patient’s illness by treating the body without excluding the
person who is experiencing the illness [1] with his/her
mind. The dualistic perspective shows traces of Cartesian
dualism: a human being consists of two incompatible sub-
stance, res cogitans and res extensa, the mind and the
body that are completely separate and distinct. This point
of view is incomplete because body and mind, biology
and psychology, nature and culture are not alternative
viewpoints. Mind and body are integrated by neural and
biochemical circuits that communicate with one another.
A full understanding of the human brain requires an inte-
grated perspective, where mind and body (reciprocally
related) fully interact with the physical and social envi-
ronment [2].
However, several questions remain unanswered: How
do the biological processes of the brain give rise to men-
tal events, and how, in turn, do social factors modulate the
biological structure of the brain? To what degree is this
biological process determined by genetic and develop-
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mental factors? To what degree is it environmentally or
socially determined? [3]. All mental processes are biolog-
ical, and therefore any alteration in these processes is nec-
essarily organic. Learning and experience have a critical
role in the regulation of gene expression. Each gene has a
double function: a template function that guarantees the
fidelity of replication and a transcriptional function that is
responsive to environmental factors [3]. Understanding
the role and mechanisms of placebo might improve the
implementation of trials and extend our knowledge in the
field of headache.
Placebo effect
There is no unique definition of “placebo”, from the Latin
“I shall please”. Gøtzsche (1994) said that “the placebo
concept as presently used cannot be defined in a logically
consistent way and leads to contradictions” [4]. A placebo
is both a pharmacologically inert substance and “any
effect attributable to a pill, potion, or procedure, but not to
its pharmacodynamic or specific properties” [5].
The tradition of placebo research goes back to the
1950s. In 1955, Henry K. Beecher, with his famous article
“The Powerful Placebo”, quantified the effects of place-
bos in a variety of diseases. By collecting data from 15
different studies, he showed that the symptoms of 35% of
1,082 patients were relieved by placebo alone [6].
There are three general reasons for clinical improve-
ment: the specific effect of the drug or other treatment
being tested, the effect due to the natural history of the
disease, or the placebo effect [7]. It should also be stressed
that there might be many factors that may create false
placebo effects such as the natural course of a disease (e.g.
spontaneous improvement, fluctuation of symptoms,
regression to the mean, habituation), additional treatment
(e.g. diet for irritable colon treatment), or patient bias (e.g.
answer of politeness and experimental subordination) [8].
There are different points of view about the use of
placebo: some think that the use of placebo in clinical tri-
als means only that some patients take medications that
are without efficacy; for others the use of placebo is often
the only way to establish the efficacy of new drugs [9].
In trials using placebo, several variables should be
considered, such as the characteristics of placebo (appear-
ance, volume, number of intake and route of administra-
tion), the effects of the ingredients used as placebo and the
ethical problems [10].
Today, the use of placebo-controlled trials in medical
settings is required in order to assess both the efficacy and
safety of drugs and to determine the extent of the thera-
peutic effect.
An absolute ethical condition in clinical placebo-con-
trolled trials is that the patients (adults or children) are not
harmed or put at significant risk during the research.
There are reports in the literature of the nocebo phenome-
non, from the Latin “I will harm”. The nocebo phenome-
non refers to symptoms or physiological changes that fol-
low the employment of an inert, chemically inactive sub-
stance that the patient believes to be an active drug [11].
Placebo therapy is not a “non-therapy”. The efficacy of
placebo is well known, but less well known is the fact that
placebo medications can produce adverse reactions [12].
Benson asserted that there are three components that make
up the placebo and nocebo effect: the first is the belief or
expectancy harboured by the patient; the second is the
belief or expectancy on the part of the physician; the third
is the belief or expectancy that is engendered by the rela-
tionship between the two [13].
It is important to differentiate between the “placebo
effect” and “non-specific effect” of drugs, because sever-
al dimensions (psychological, cognitive, affective motiva-
tional) can modulate a personal response to certain situa-
tions or stimuli. Expectancy of drug efficacy and individ-
ual differences in suggestibility were found to contribute
significantly to the magnitude of placebo analgesia [14].
Personality factors, mood disorders, anxiety and emotion-
al distress can be associated with placebo effects [15].
Subjects with depression often have a pessimistic and
negative concept of events and an external locus of con-
trol; an anxious person can experience somatization and
view the placebo as a threat, thereby amplifying the nega-
tive symptoms (tachycardia, dyspnoea, sweating) [15].
The placebo response embraces a variety of these non-
specific factors which will combine in many cases to pro-
duce an improvement; this is true in all fields of medicine
but the effects can be particularly potent in psychiatry
[16]. Psychiatric disorders have a high placebo response:
endogenous-type depression and neurotic or reactive
depression have placebo response rates around 30% and
70%, respectively [17], generalized anxiety disorder
varies widely between 18% and 67% [18], panic attack
between 20% and 134% with a median of 56% [19], and
social phobia between 7% and 43% [20].
The placebo effects are not merely an aspecific
response; in studies on pain and analgesia, the neurophys-
iological mechanisms of the placebo effect were investi-
gated. Some aspects of placebo analgesia are dependent on
the endogenous opioid system. Expectation cues and/or
morphine conditioning produced placebo responses that
were completely antagonized by naloxone; by contrast,
non-opioid conditioning alone produced placebo responses
that were naloxone-insensitive. Therefore, placebo analge-
sia could be activated by the opioid or non-opioid system:
the expectation may also trigger endogenous opioids [21].
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Microinjection of opioid directly into the nucleus
accumbens was shown to induce antinociception, and
microinjection of the opioid antagonist naloxone into the
nucleus accumbens was seen to attenuate the antinocicep-
tive effect. The nucleus accumbens, an important compo-
nent of the mesolimbic dopaminergic reward system,
plays a role in pain modulation [22].
Placebo analgesia is associated with patterns of cere-
bral blood-flow activation (particularly the rostral anteri-
or cingulated cortex) similar to those seen after injection
of an active opioid [23].
Positron emission tomography performed on 17
patients with unipolar depression after 6 weeks of fluoxe-
tine or placebo (double-blind trial) showed the same bio-
chemical changes in different cerebral regions for both
treatments [24]. Roughly 50–75% of the efficacy of anti-
depressant medications represents the placebo effect. In a
double-blind placebo-controlled study, 38% of the
patients with depression were placebo responders (vs.
52%); placebo responders showed a significant increase in
prefrontal cordance [25].
The use of placebo is particularly difficult when con-
cerning children: development markedly influences the
absorption, distribution, metabolism and excretion of
drugs. A rational drug therapy in children and adoles-
cents requires individualizing treatment as well as rec-
ognizing individual (comorbidity, concurrent medica-
tions), developmental (pharmacodynamic, pharmacoki-
netic) and environmental factors (diet, environmental
contaminants) that could influence drug disposition and
response.
Placebo and headache
Placebo-controlled trials are necessary when the studied
population has a high placebo response rate with frequent
spontaneous remissions and existing therapies are only
partly effective: all these criteria are fulfilled by
headache [26].
A study evaluating the placebo response in acute
treatment of migraine without or with aura and episod-
ic tension-type headache showed pain relief after place-
bo administration in all groups (50%, 23.3% and 26.7%,
respectively) [27]. In adults, 2 h after treatment, posi-
tive headache response to placebo ranges between 7%
and 50% of migraineurs (average response rate of 30%)
and pain-free response to placebo ranges between 7%
and 17% (average response of 9%) [28]. In cluster
headache, the placebo response varies from 7% to 42%
(acute therapy) and from 14% to 43% (prophylactic
treatment) [29].
The placebo effect for migraine prevention in children
has been estimated to be as high as 40%–50% [30]. High
responses to placebo are present in trials on treatment with
triptans; on adults, trials on triptans record a response to
placebo (combined data) ranging from 18% to 35% [31].
Trials on triptans showed a higher placebo effect in chil-
dren and adolescents than in adults: in children, the
response to placebo ranges from 14% to 40% and in ado-
lescents from 25% to 61%.
This finding may stimulate intriguing questions on
(a) the diversity between adults and children and/or ado-
lescents in the explanation of such different responses to
drugs, (b) which factors are involved, and (c) the way of
limiting likely shortcomings in findings. In a review of
109 double-blind, placebo-controlled drug trials, an
average of 19% of patients on placebo reported adverse
side effects; headache led the list at 7% [15]. Reuter et
al. [32] analysed the adverse events of placebo in acute
and preventive randomized, double-blind, placebo-con-
trolled studies for migraine treatment. From 10% to
30% of subjects reported adverse events after placebo,
such as (most common) nausea, phono- and photopho-
bia [32].
On one hand, the high response rates to placebo
show the critical importance of realizing placebo-con-
trolled trials in the field of headache research. On the
other, the wide variability in percentage range stresses
the probable differences in methodology that should be
better controlled in the implementation of trials in order
to yield more accurate findings. For example, the high
psychiatric comorbidity shown by headache sufferers,
both adult and pediatric patients [33–35], should be con-
sidered in the trials on headache, because of the above-
mentioned high response of psychiatric patients to
placebo.
It is noteworthy that placebo induces biochemical
changes, not only a response “by suggestion”. A better
understanding of such changes in the central nervous sys-
tem may contribute to the comprehension of the patho-
physiology of headache. Toward this aim, we should try
gain a better understanding of which factors distinguish
placebo responders, so as to improve the implementation
of trials on headache and avoid bias related to personality
factors of proband subjects.
A better understanding of placebo mechanisms could
also show a likely common aetiology of both disorders,
such as the hypothesized implication of the serotoninergic
system in both migraine and depression [36–37].
To date, we may only formulate questions on the
involvement of placebo and the consequences for the
pathophysiology of headache. Answers may offer a new
strategy in the implementation of trials and new insight on
the pathophysiology of headache.
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